首页 奥麦罗制药(usOMER)-基本信息

奥麦罗制药(usOMER)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-16 11:49

行情信息

今开价:18.21

最高价:18.5

成交量:1.14569E8

昨收价:17.99

最低价:17.77

最新价:18.06

行情图标
概要信息

中文名称:奥麦罗制药


英文名称:Omeros


行业:医疗


简介:Omeros Corporation是一家临床阶段的生物制药公司,致力于发现、开发和商业化针对炎症、中枢神经系统凝血紊乱的产品


电话:1-206-6765000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Omeros Corporation主要研发抑制发炎及中枢神经系统的药物和疗法。奥麦罗制药公司的商业化阶段的产品包括: Omidria——用于白内障手术的人工晶体置换。Omeros公司的临床阶段产品包括: OMS721——用于治疗各种补体介导的病症,包括补体介导的血栓微血管病,目前处于II期临床阶段; OMS824——用于治疗精神分裂症和亨廷顿氏病,目前处于II期临床试验阶段; OMS103——用于关节镜手术(如部分半月板切除术),已完成III期临床试验; OMS405——用于成瘾和药物滥用的治疗和预防,目前处于II期临床试验阶段; OMS201——用于泌尿外科疾病(如输尿管镜去除输尿管或肾结石),目前已经完成I / II临床试验。Omeros公司的临床前阶段产品包括: OMS527——用于治疗成瘾和强迫症,以及用于运动障碍,如帕金森氏病; OMS616——用于因手术、外伤或其他情况导致的失血; OMS906——用于阵发性睡眠性血红蛋白尿症和其他替代途径疾病的治疗; GPR17——用于脱髓鞘疾病的治疗; G蛋白偶联受体平台——可跨越治疗领域治疗多种疾病和障碍; 抗体平台——用于单克隆抗体的发现。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-06 Kelbon (Marcia S) General Counsel Buy 10000 6.05
2018-08-30 Kelbon (Marcia S) General Counsel Buy 7529 4.10
2018-08-30 Kelbon (Marcia S) General Counsel Sell 2192 25.31
2018-08-30 Kelbon (Marcia S) General Counsel Buy 8000 6.05
2018-08-30 Kelbon (Marcia S) General Counsel Sell 5337 25.93
2018-08-29 Kelbon (Marcia S) General Counsel Buy 35000 4.10
2018-08-29 Kelbon (Marcia S) General Counsel Sell 35000 24.45
2018-07-26 Kelbon (Marcia S) General Counsel Sell 5723 21.73
2018-07-26 Kelbon (Marcia S) General Counsel Buy 5723 4.10
2018-07-25 Kelbon (Marcia S) General Counsel Sell 35000 21.53
2018-07-25 Kelbon (Marcia S) General Counsel Buy 8000 6.05
2018-07-25 Kelbon (Marcia S) General Counsel Buy 35000 4.10
2018-07-11 Kelbon (Marcia S) General Counsel Buy 4277 4.10
2018-07-11 Kelbon (Marcia S) General Counsel Sell 4277 21.48
2018-05-14 Jacobsen (Michael A) Officer Sell 12812 24.95
2018-05-14 Jacobsen (Michael A) Officer Buy 12812 9.37
2018-05-14 Jacobsen (Michael A) Officer Buy 5000 9.37
2018-05-13 Jacobsen (Michael A) Officer Buy 10980 9.37
2018-05-13 Jacobsen (Michael A) Officer Sell 10980 22.45
2018-01-03 Jacobsen (Michael A) Officer Buy 1000 9.37
2018-01-02 Jacobsen (Michael A) Officer Sell 1020 22.45
2018-01-02 Jacobsen (Michael A) Officer Buy 1020 9.37
2018-01-02 Kelbon (Marcia S) General Counsel Buy 62528 9.37
2018-01-02 Kelbon (Marcia S) General Counsel Buy 5004 6.05
2018-01-02 Kelbon (Marcia S) General Counsel Sell 62528 21.45

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
American Financial Group Inc 340284 0.69% -- -- 2019-03-31
State Street Corporation 1056639 2.15% -74011 -6.55% 2019-03-31
Vanguard Investments Australia Ltd 1318147 2.69% -58 -- 2019-07-31
Consonance Capital Management LP 2124619 4.33% 2124619 -- 2019-03-31
BlackRock Fund Advisors 2174211 4.43% 10576 0.49% 2019-07-31
Vanguard Group Inc 2372503 4.84% 43769 1.88% 2019-03-31
D. E. Shaw & Co LP 2585438 5.27% 673194 35.20% 2019-03-31
BlackRock Inc 3818051 7.78% -171155 -4.29% 2019-03-31
Ingalls & Snyder LLC 5077257 10.35% -93150 -1.80% 2019-03-31
Northern Trust Investments Inc 938258 1.91% 16147 1.75% 2019-07-31
Millennium Management LLC 748292 1.53% -364292 -32.74% 2019-03-31
CPCM, LLC 721934 1.47% -3614 -0.50% 2019-03-31
UBS Group AG 403411 0.82% 1768 0.44% 2019-03-31
State Street Global Advisors 444618 0.91% -- -- 2019-07-31
Fidelity Management & Research Company 540619 1.10% 23594 4.56% 2019-07-31
Geode Capital Management, LLC 569289 1.16% -463975 -44.90% 2019-03-31
Northern Trust Investments N A 630568 1.29% 13395 2.17% 2019-03-31
Northern Trust Corp 630568 1.29% 13395 2.17% 2019-03-31
Stifel Nicolaus Investment Advisors 634491 1.29% 190813 43.01% 2019-03-31
Stifel Financial Corp 634491 1.29% 190813 43.01% 2019-03-31
BlackRock Asset Management Canada Ltd 1091009 2.22% 240 0.02% 2019-05-31
Royal Bank of Canada 694793 1.42% 693085 40578.75% 2018-12-31
Citadel Advisors Llc 515279 1.05% 515279 -- 2018-09-30
Cormorant Asset Management, LLC 1000000 2.04% -314118 -23.90% 2018-09-30
TIAA-CREF Investment Management LLC 488748 1.00% 248634 103.55% 2018-09-30
Susquehanna Financial Group, LLLP 685876 1.40% -269267 -28.19% 2018-09-30
Susquehanna International Group, LLP 685876 1.40% -269267 -28.19% 2018-09-30
BlackRock Institutional Trust Company NA 1268387 2.59% -2351 -0.19% 2018-06-30
UBS Securities LLC 382636 0.78% -7810 -2.00% 2018-09-30
Foresite Capital Management IV, LLC 356000 0.73% 356000 -- 2018-09-30
Northern Trust Asset Management 112184 0.23% -326 -0.29% 2018-07-31
BNY Mellon Investment Management 133282 0.27% 8079 6.45% 2018-06-30
Charles Schwab Investment Management Inc 239828 0.49% 17150 7.70% 2018-06-30
Morgan Stanley & Co Inc 240148 0.50% 92103 62.21% 2018-06-30
State Street Corp 1079522 2.23% -133006 -10.97% 2018-06-30
Capital Impact Advisors, LLC 95755 0.20% -- -- 2018-06-30
OZ Management LLC 87400 0.18% -- -- 2018-06-30
Jefferies & Company Inc 115708 0.24% 115708 -- 2018-03-31
Alps Advisors Inc 76654 0.13% -- -- 2018-08-10
First Trust Advisors L.P. 105884 0.22% 105884 -- 2017-12-31
Davenport & Company LLC 79400 0.16% -- -- 2017-12-31
Candriam Luxembourg 85370 0.18% -8000 -8.57% 2017-12-31
Mutual Of America Capital Management LLC 109137 0.23% 761 0.70% 2017-12-31
Group One Trading, LP 150913 0.31% 70899 88.61% 2017-12-31
Adage Capital Partners Gp LLC 150000 0.31% -- -- 2017-12-31
Chicago Equity Partners LLC 195120 0.40% -755 -0.39% 2017-12-31
Tocqueville Asset Management L.P. 290119 0.60% -190777 -39.67% 2017-12-31
Great American Life Insurance Company 429061 0.98% -- -- 2016-12-31
Invesco PowerShares Capital Mgmt LLC 135876 0.28% 135876 -- 2017-09-30
EAM Investors 202025 0.42% 47146 30.44% 2017-09-30
EcoR1 Capital, LLC 450000 0.94% 450000 -- 2017-09-30
Arrowstreet Capital Limited Partnership 125643 0.26% 125643 -- 2017-09-30
Quantitative Investment Management, LLC 149700 0.34% 149700 -- 2017-06-30
Think Investments LP 524400 1.18% 524400 -- 2017-06-30
BMO Asset Management Corp. 1972215 4.60% 330598 20.14% 2016-09-30
Brown Investment Advisory Incorporated 587508 1.37% 43745 8.04% 2016-09-30
RTW INVESTMENTS, LLC 383012 0.89% -143776 -27.29% 2016-09-30
Davidson D A & Co 270245 0.63% 7723 2.94% 2016-09-30
Manufacturers Life Insurance Co 244976 0.57% -1067 -0.43% 2016-09-30
BlackRock Advisors LLC 166765 0.39% 7308 4.58% 2016-09-30
BlackRock, Inc. 1953307 4.00% 42875089 -- 1999-11-30
Ingalls & Snyder, LLC 2347987 4.00% 51538315 0.10% 1999-11-30
Invesco, Ltd. 3107443 4.00% 68208374 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Schwab Small Cap Index Fund 96875 0.20% 2668 2.83% 2019-06-30
PNC Multi Factor Small Cap Core 191075 0.39% -20630 -9.74% 2019-05-31
NT R2000 Growth Index Fund - Non-Lending 195414 0.40% -5714 -2.84% 2019-06-30
State Street Russell Small/Mid Cap 196930 0.40% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 427983 0.87% 6060 1.44% 2019-07-30
iShares Nasdaq Biotechnology ETF 484284 0.99% 6651 1.39% 2019-07-30
Vanguard Extended Market Index Fund 643234 1.31% -387 -0.06% 2019-06-30
iShares Russell 2000 ETF 1015602 2.07% 1991 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 1308136 2.67% -- -- 2019-06-30
State Street Russell Small Cap 190507 0.39% -- -- 2019-06-30
Fidelity 186714 0.38% 23599 14.47% 2019-04-30
SPDR 104176 0.21% -- -- 2019-07-30
iShares Micro-Cap ETF 117866 0.24% -- -- 2019-07-30
ERShares US Small Cap Fund 119484 0.24% -17086 -12.51% 2019-03-31
Vanguard Health Care Index Fund 120019 0.24% -1281 -1.06% 2019-06-30
Schwab US Small-Cap ETF 133689 0.27% -- -- 2019-07-30
Northern Trust Russell 2000 Index DC NL 135429 0.28% 1191 0.89% 2019-06-30
NT R2000 Growth Index Fund - Lending 140653 0.29% 3883 2.84% 2019-06-30
NT R2000 Index Fund - NL 178391 0.36% 2171 1.23% 2019-06-30
Russell 2000 Index Non-Lendable Fund E 94873 0.19% 463 0.49% 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 941376 1.92% -1584 -0.17% 2019-05-30
CREF Stock Account 206837 0.42% -7042 -3.29% 2019-03-31
iShares US Pharmaceuticals ETF 106790 0.22% -222 -0.21% 2019-03-29
The Vanguard - Russell 2000 Grwth Idx CF 82179 0.17% 1050 1.29% 2019-02-28
AXA 2000 Managed Volatility Portfolio 72435 0.15% -- -- 2019-01-31
Vanguard Russell 2000 Index Fund 54465 0.11% -828 -1.50% 2019-01-31
Vanguard Instl Total Stock Market Idx Fd 60160 0.12% -- -- 2019-01-31
Master Small Cap Index Series 57883 0.12% -- -- 2019-01-31
TIAA-CREF Small-Cap Blend 60948 0.12% -- -- 2018-12-31
Entrepreneur US Small Cap Fund 95755 0.20% -- -- 2018-09-30
iShares Russell 2000 Small-Cap Index Fd 57883 0.12% 2676 4.85% 2018-12-31
Invesco DWA SmallCap Momentum ETF 57281 0.12% -- -- 2018-12-30
ALPS Medical Breakthroughs ETF 78470 0.16% -- -- 2018-11-30
Candriam Eqs L Biotechnology 84000 0.17% -- -- 2018-02-28
Vanguard Market Neutral Fund 155276 0.32% 89700 136.79% 2018-03-31
Mutual of America Small Cap Growth Fund 101107 0.21% 1549 1.56% 2017-12-31
Invesco DWA Healthcare Momentum ETF 101687 0.21% -- -- 2017-09-30
Vanguard Total Stock Mkt Idx 1158369 2.39% -- -- 2018-07-31
iShares Nasdaq Biotechnology 546702 1.12% -1041 -0.19% 2018-09-12
Vanguard Extended Market Idx Inv 600526 1.24% 801 0.13% 2018-07-31
iShares Russell 2000 Growth 437092 0.90% -421 -0.10% 2018-09-12
iShares US Pharmaceuticals 239177 0.49% -- -- 2018-09-12
CREF Stock R1 208055 0.43% -2417 -1.15% 2018-07-31
iShares Micro-Cap 121691 0.25% -- -- 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 112184 0.23% -326 -0.29% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 143388 0.32% 3690 2.64% 2017-06-30
Vanguard Health Care ETF 101960 0.21% 3209 3.25% 2018-07-31
Fidelity Spartan 96420 0.20% -- -- 2018-07-31
Schwab Small Cap Index 86800 0.18% -- -- 2018-07-31
Entrepreneur US All Cap Institutional 95755 0.20% -- -- 2018-06-30
The Vanguard Russell 2000 Growth Index 82141 0.17% 1044 1.29% 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 70786 0.15% -- -- 2018-07-31
AXA 2000 Managed Volatility K 68089 0.14% -- -- 2018-07-31
BlackRock Extended Equity Market K 77655 0.16% 16985 28.00% 2018-06-30
Vanguard Market Neutral I 155276 0.32% 89700 136.79% 2018-03-31
BlackRock Russell 2000 67541 0.14% -2443 -3.49% 2018-06-30
BioShares 41704 0.09% -- -- 2018-06-01
Mutual of America Small Cap Growth 101107 0.21% 1549 1.56% 2017-12-31
Vanguard Strategic Small-Cap Equity Inv 43475 0.09% 43475 -- 2017-12-31
JNL/Mellon Capital Healthcare Sector B 41519 0.09% 10410 33.46% 2017-12-31
BlackRock Russell 2500 61830 0.13% 316 0.51% 2017-12-31
iShares Russell 2000 Value 138647 0.34% -552 -0.40% 2017-02-07
Tocqueville Alternative Strategies 75000 0.19% 10000 15.38% 2016-03-31
JNL Multi-Manager Small Cap Value A 81475 0.19% 7165 9.64% 2016-09-30
SSgA Russell Small/Mid Cap Index Fund Tr 87400 0.20% -- -- 2015-06-30
Mackenzie US Growth Class 92000 0.20% -- -- 2015-08-31
Principal SmallCap Growth Fund I 115165 0.30% 1431 1.30% 2015-10-31
Fidelity Spartan® Extended Mkt Indx Fd 129021 0.30% -- -- 2015-09-30
Tocqueville Fund 150000 0.40% -- -- 2015-09-30
BMO Small Cap Growth Fund 383994 1.00% 383994 -- 2015-09-30
iShares Russell 2000 (AU) 603295 1.70% -762 -0.10% 2015-11-19
SPDR® S&P Pharmaceuticals ETF 1483826 4.30% -- -- 2015-11-19

Arnold C. Hanish Arnold C. Hanish is on the board of Omeros Corp. and Member-Audit Quality Review Council at Deloitte & Touche LLP. He previously was Chief Accounting Officer & Vice President of Eli Lilly & Co. He received an undergraduate degree from the University of Cincinnati (Ohio).
Timothy M. Duffy Founder of Pacific Crest Corp. and Pacific Crest Ventures, Timothy M. Duffy is Vice President-Business Development of Omeros Corp. In the past Mr. Duffy occupied the position of Managing Director at Pacific Crest Ventures, Manager-Customer Marketing at Procter & Gamble Co., Managing Director at Pacific Crest Corp., Vice President-Business Development of Prometheus Laboratories, Inc. and Chief Business Officer for MDRNA, Inc. Timothy M. Duffy received an undergraduate degree from Loras College.
Leroy E. Hood Dr. Leroy E. Hood, is President at The Institute for Systems Biology, President at ISB Accelerator Corp., an Advisor at InterWest Partners, Co-Founder at Rosetta Inpharmatics LLC, Founder at University of Washington, Co-Founder at Systemix, Inc., Co-Founder at Darwin Molecular Technologies, Inc., a Member at National Academy of Sciences, a Member at American Philosophical Society, a Member at The American Association of Arts & Sciences, a Member at National Academy of Engineering, a Member at Institute of Medicine, a Director at Accelerator Corp., an Advisor at OVP Venture Partners, a Director at Integrated Diagnostics, Inc. (Washington), and a Director at Science Foundation Arizona. He is on the Board of Directors at NABsys, Inc., Omeros Corp., Intelligent Medical Devices, Inc., Integrated Diagnostics, Inc. (Washington), and Geospiza, Inc. Dr. Hood was previously employed as Co-Founder by Applied Biosystems, Inc., a Principal by Rosetta Genomics Ltd., a Principal by Amgen, Inc., a Principal by Applied Biosystems, Inc., and a Principal by Darwin Resources, Inc. He also served on the board at Icoria, Inc., CTI Molecular Imaging, Inc., Lynx Therapeutics, Inc., and NimbleGen Systems, Inc. Dr. Hood received his undergraduate degree from the California Institute of Technology, a doctorate degree from Johns Hopkins University, and a doctorate degree from the California Institute of Technology.
Michael A. Jacobsen Michael A. Jacobsen is Principal Financial Officer, Treasurer & VP at Omeros Corp. In his past career he occupied the position of Secretary, Chief Accounting Officer & VP-Finance at Sarepta Therapeutics, Inc., Chief Accounting Officer & Vice President for ZymoGenetics, Inc. and Senior Director-Finance & Corporate Controller at ICOS Corp. He received an undergraduate degree from Idaho State University.
Rajiv J. Shah Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine.
Thomas J. Cable Thomas J. Cable is an entrepreneur who founded Cable & Howse Ventures, Cable, Howse & Ragen, Inc. and Washington Research Foundation. Mr. Cable is on the board of Omeros Corp., Institute for Systems Biology and Washington Research Foundation. In his past career Thomas J. Cable was Partner at Cable, Howse & Ragen, Inc. and Chairman for WRF Capital. Mr. Cable received an undergraduate degree from Harvard University and an MBA from Stanford Graduate School of Business.
George A. Gaitanaris George A. Gaitanaris founded Primal, Inc. and Nura, Inc. Presently, Dr. Gaitanaris occupies the position of Chief Scientific Officer & Vice President-Science at Omeros Corp. In his past career he held the position of President & Chief Scientific Officer at Primal, Inc., Chief Scientific Officer at Nura, Inc. and Staff Scientist at National Cancer Institute. George A. Gaitanaris received a graduate degree and a doctorate from Columbia University and a doctorate from Aristotle University of Thessaloniki.
Gregory A. Demopulos Gregory A. Demopulos founded Omeros Corp. Presently, he is Chairman, President & Chief Executive Officer at this company. He is also on the board of Onconome, Inc., Smead Funds Trust, Tessera, Inc. and Northwest NeuroNeighborhood and Member of Seattle Cardiology. He received an undergraduate degree from Stanford University and a doctorate from Stanford University School of Medicine.
Marcia S. Kelbon Presently, Marcia S. Kelbon holds the position of Vice President-Legal Affairs at Omeros Corp. She is also Member of Washington State Bar Association. Ms. Kelbon previously was Partner at Christensen O'Connor Johnson & Kindness PLLC. She received a graduate degree from the University of Washington and an undergraduate degree from The Pennsylvania State University.
Ray Aspiri Ray Aspiri founded Tempress Technologies, Inc. He is on the board of Omeros Corp. Mr. Aspiri previously was Chairman & Chief Executive Officer at Tempress, Inc., Chairman & Chief Executive Officer for Tempress Associates, Inc. and Chairman at Tempress Technologies, Inc.
Peter A. Demopulos Peter A. Demopulos occupies the position of Member of Seattle Cardiology. He is also on the board of Omeros Corp. and Assistant Professor at UW Medicine. He received an undergraduate degree from Stanford University and a doctorate from Stanford University School of Medicine.
Rajiv J. Shah Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine.
J. Steven Whitaker J. Steven Whitaker is Head-Clinical Aspects at Omeros Corp. In the past Dr. Whitaker held the position of Chief Medical Officer & VP-Clinical Development at Allon Therapeutics, Inc. and Divisional Vice President at ICOS Corp. Dr. Whitaker received a graduate degree from the University of Washington, an undergraduate degree from Butler University and a doctorate from The Indiana University School of Medicine.
Thomas F. Bumol Thomas F. Bumol is on the board of Omeros Corp., PanTheryx, Inc. and Allen Institute For Immunology. Dr. Bumol previously held the position of Senior VP-Biotechnology & Autoimmunity Research at Eli Lilly & Co. President of Applied Molecular Evolution, Inc. and President-Applied Molecular Evolution at Lilly Research Laboratories (both are subsidiaries of Eli Lilly & Co.). Thomas F. Bumol received an undergraduate degree from the University of Michigan and a doctorate from the University of Minnesota.
Peter B. Cancelmo Presently, Peter B. Cancelmo is Secretary, Vice President & General Counsel at Omeros Corp. Mr. Cancelmo previously was Principal at Garvey Schubert Barer. Mr. Cancelmo received a graduate degree from Boston University and an undergraduate degree from St. Michael's College.
Timothy M. Duffy Founder of Pacific Crest Corp. and Pacific Crest Ventures, Timothy M. Duffy is Vice President-Business Development of Omeros Corp. In the past Mr. Duffy occupied the position of Managing Director at Pacific Crest Ventures, Manager-Customer Marketing at Procter & Gamble Co., Managing Director at Pacific Crest Corp., Vice President-Business Development of Prometheus Laboratories, Inc. and Chief Business Officer for MDRNA, Inc. Timothy M. Duffy received an undergraduate degree from Loras College.
Catherine A. Melfi Currently, Catherine A. Melfi is Chief Regulatory Officer & VP-Regulatory Affairs at Omeros Corp. Dr. Melfi previously held the position of Scientific Director-Regulatory Affairs at Eli Lilly & Co. She received a doctorate from the University of North Carolina at Chapel Hill and an undergraduate degree from John Carroll University.
Rajiv J. Shah Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine.
Michael A. Jacobsen Michael A. Jacobsen is Principal Financial Officer, Treasurer & VP at Omeros Corp. In his past career he occupied the position of Secretary, Chief Accounting Officer & VP-Finance at Sarepta Therapeutics, Inc., Chief Accounting Officer & Vice President for ZymoGenetics, Inc. and Senior Director-Finance & Corporate Controller at ICOS Corp. He received an undergraduate degree from Idaho State University.
Timi Edeki Timi Edeki is Vice President-Clinical Development at Omeros Corp. In the past he held the position of Senior Director-Research & Development at AstraZeneca Diagnostics, Associate Director at Abbott Laboratories and Professor at Chicago Medical School. He received a doctorate from the University of London and an undergraduate degree from the University of Lagos.
Eckhard S. D. Leifke Currently, Eckhard S. D. Leifke holds the position of Chief Medical Officer & VP-Clinical Development at Omeros Corp. In the past he was Vice President for Sanofi, Inc. Dr. Leifke received a doctorate from the University of Freiburg.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐